These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25876451)

  • 61. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
    Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
    Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
    Meuth SG; Ruck T; Aktas O; Hartung HP
    Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.
    Montalban X; Leist TP; Cohen BA; Moses H; Campbell J; Hicking C; Dangond F
    Neurol Neuroimmunol Neuroinflamm; 2018 Sep; 5(5):e477. PubMed ID: 30027104
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.
    Kremenchutzky M; O'Connor P; Hohlfeld R; Zhang-Auberson L; von Rosenstiel P; Meng X; Grinspan A; Hashmonay R; Kappos L
    Mult Scler Relat Disord; 2014 May; 3(3):341-9. PubMed ID: 25876471
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 66. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers.
    Habek M; Drulovic J; Brecl Jakob G; Barbov I; Radulovic L; Rajda C; Rejdak K; Turčáni P
    Neurol Ther; 2023 Feb; 12(1):25-37. PubMed ID: 36394714
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
    Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL
    Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.
    Novakovic AM; Krekels EH; Munafo A; Ueckert S; Karlsson MO
    AAPS J; 2017 Jan; 19(1):172-179. PubMed ID: 27634384
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).
    Tsivgoulis G; Deftereos S; Gobbi C; Gulowsen Celius E; Kulakowska A; Maniscalco G; Mendes I; Grigoriadis N
    J Cent Nerv Syst Dis; 2022; 14():11795735211069441. PubMed ID: 35392050
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
    de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35701185
    [TBL] [Abstract][Full Text] [Related]  

  • 74. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM; Constantinescu CS; Raychaudhuri A; Kim L; Fidelus-Gort R; Kasper LH;
    Lancet Neurol; 2008 Sep; 7(9):796-804. PubMed ID: 18703004
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transdermal application of myelin peptides in multiple sclerosis treatment.
    Walczak A; Siger M; Ciach A; Szczepanik M; Selmaj K
    JAMA Neurol; 2013 Sep; 70(9):1105-9. PubMed ID: 23817921
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials.
    Viglietta V; Miller D; Bar-Or A; Phillips JT; Arnold DL; Selmaj K; Kita M; Hutchinson M; Yang M; Zhang R; Dawson KT; Sheikh SI; Fox RJ; Gold R
    Ann Clin Transl Neurol; 2015 Feb; 2(2):103-18. PubMed ID: 25750916
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates.
    Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A
    Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Freedman MS; Coyle PK; Comi G; L Scarberry S; Damian D; Hyvert Y; Dangond F; Galazka A; Jack D; Lebson LA; Leist TP
    Mult Scler J Exp Transl Clin; 2021; 7(1):2055217321990852. PubMed ID: 33717501
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER.
    Ziemssen T; Posevitz-Fejfár A; Chudecka A; Cepek L; Reifschneider G; Grothe C; Richter J; Wagner T; Müller B; Penner IK
    Mult Scler Relat Disord; 2024 Oct; 90():105812. PubMed ID: 39151238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.